Akhilesh Tamrakar

Dr. Akhilesh Tamrakar

Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow-226031, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2014 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
ATAkhilesh Tamrakar
Akhilesh Tamrakar
CMChandan K Maurya
Chandan K Maurya
ARAmit K Rai
Amit K Rai
Protein tyrosine phosphatase 1B (PTP1B) plays an important role in the negative regulation of insulin signal transduction pathway and has emerged as novel therapeutic strategy for the treatment of type 2 diabetes. PTP1B inhibitors enhance the sensibility of insulin receptor (IR) and have favorable curing effect for insulin resistance-related diseases. A large number of PTP1B inhibitors, either synthetic or isolated as bioactive agents from natural products, have developed and investigated for their ability to stimulate insulin signaling. This review includes an updated summary (2011 - 2014) of PTP1B inhibitors that have been published in patent applications, with an emphasis on their chemical structure, mode of action and therapeutic outcomes. The usefulness of PTP1B inhibitors as pharmaceutical agents for the treatment of type 2 diabetes is also discussed. PTP1B inhibitors show beneficial effects to enhance sensibility of IR by restricting the activity of enzyme and have favorable curing effects. However, structural homologies in the catalytic domain of PTP1B with other protein tyrosine phosphatases (PTPs) like leukocyte common antigen-related, CD45, SHP-2 and T-cell-PTP present a challenging task of achieving selectivity. Thus, for therapeutic application of PTP1B inhibitors, highly selective molecules exhibiting desired effects without side effects are expected to find clinical application.

26 April 2015 in Apoptosis
Verified
Journal Article
Closed access
PDF file
NJNatasha Jaiswal
Natasha Jaiswal
CMChandan K. Maurya
Chandan K. Maurya
DADeepti Arha
Deepti Arha
DADeepa R. Avisetti
Deepa R. Avisetti
APAyyappan Prathapan
Ayyappan Prathapan
ATAkhilesh Tamrakar
Akhilesh Tamrakar

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KFKevin P. Foley
Kevin P. Foley
YCYong Chen
Yong Chen
NBNicole G. Barra
Nicole G. Barra
MHMark Heal
Mark Heal
KKKieran Kwok
Kieran Kwok
JSJonathan D. Schertzer
Jonathan D. Schertzer
Obesity associates with inflammation, insulin resistance and higher blood lipids. It is unclear if immune responses facilitate lipid breakdown and release from adipocytes via lipolysis in a separate way from hormones or adrenergic signals. We found that an ancient component of ER stress, inositol-requiring protein 1 (IRE1), discriminates inflammation-induced adipocyte lipolysis versus lipolysis from adrenergic or hormonal stimuli. Our data show that inhibiting IRE1 kinase activity was sufficient to block adipocyte-autonomous lipolysis from multiple inflammatory ligands, including bacterial components, certain cytokines, and thapsigargin-induced ER stress. IRE1-mediated lipolysis was specific for inflammatory triggers since IRE1 kinase activity was dispensable for isoproterenol and cAMP-induced lipolysis in adipocytes and mouse adipose tissue. IRE1 RNase activity was not associated with inflammation-induced adipocyte lipolysis. Inhibiting IRE1 kinase activity blocked NF-κB activation, interleukin-6 secretion, and adipocyte-autonomous lipolysis from inflammatory ligands. Inflammation-induced lipolysis mediated by IRE1 occurred independently from changes in insulin signaling in adipocytes, suggesting that inflammation can promote IRE1-mediated lipolysis independent of adipocyte insulin resistance. We found no role for canonical unfolded protein responses or ABL kinases in linking ER stress to IRE1-mediated lipolysis. Adiponectin-Cre-mediated IRE1 knockout in mice showed that adipocyte IRE1 was required for inflammatory ligand-induced lipolysis in adipose tissue explants and that adipocyte IRE1 was required for approximately half of the increase in blood triglycerides after a bacterial endotoxin-mediated inflammatory stimulus in vivo. Together, our results show that IRE1 propagates an inflammation-specific lipolytic program independent from hormonal or adrenergic regulation. Targeting IRE1 kinase activity may benefit metabolic syndrome and inflammatory lipid disorders.

19 May 2012 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
NJNatasha Jaiswal
Natasha Jaiswal
CMChandan K. Maurya
Chandan K. Maurya
KVK. Venkateswarlu
K. Venkateswarlu
PSP. Sukanya
P. Sukanya
ASArvind K. Srivastava
Arvind K. Srivastava
ATAkhilesh Tamrakar
Akhilesh Tamrakar

1 September 2014 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
CMChandan Kumar Maurya
Chandan Kumar Maurya
RSRohit Singh
Rohit Singh
NJNatasha Jaiswal
Natasha Jaiswal
KVK. Venkateswarlu
K. Venkateswarlu
TNTadigoppula Narender
Tadigoppula Narender
ATAkhilesh Tamrakar
Akhilesh Tamrakar

21 February 2012 in Natural Product Research
Verified
Journal Article
Closed access
NJNatasha Jaiswal
Natasha Jaiswal
VBVikram Bhatia
Vikram Bhatia
SSSwayam Srivastava
Swayam Srivastava
ASArvind Kumar Srivastava
Arvind Kumar Srivastava
ATAkhilesh Tamrakar
Akhilesh Tamrakar
The antidiabetic effect of the ethanolic extract of Eclipta alba (EEA) on hyperglycaemia and diabetic nephropathy was investigated in streptozotocin-induced diabetic rats. Single-dose treatment of EEA to streptozotocin-induced diabetic rats lowered the blood glucose level by 17.6% (p < 0.05) at 250 mg kg−1 dose after 5 h post oral administration. Treatment of animals after 10 weeks of STZ-treatment with EEA (250 mg kg−1) for 21 days significantly reduced the elevated levels of blood glucose, %HbA1C, urea, uric acid and creatinine, and significantly increased the depressed serum insulin level. The extract exerted a significant inhibitory effect on alpha-glucosidase in a noncompetitive manner with an IC50 value of around 54 µg mL−1 and was found inhibitory to eye lens aldose reductase with an IC50 value of around 4.5 µg mL−1. The results suggest that EEA possesses antidiabetic effect associated with alpha-glucosidase and aldose reductase inhibition.